Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.63 |
| ▸ | WDR5 | P61964 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.63 |
| ▸ | NPY1R | P25929 | 2/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.63 |
| ▸ | HTR3A | P46098 | 2/20 | 0.63 |
| ▸ | FASN | P49327 | 2/20 | 0.63 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | IDE | P14735 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30905609 | 1.00 | KMT2A (0.63) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL6600439 | 0.99 | CYP2C9 (0.62) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL6600434 | 0.99 | KMT2A (0.62) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL10121508 | 0.89 | KMT2A (0.62) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL23988420 | 0.88 | CYP2C9 (0.51) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL23988519 | 0.86 | CYP2C9 (0.53) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL5414007 | 0.85 | KMT2A (0.60) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL23988509 | 0.84 | CYP2C9 (0.47) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL2851048 | 0.84 | KMT2A (0.59) | KMT2ACYP2C9WDR5ALDH1A1LMNA | |
| SCHEMBL2851052 | 0.84 | KMT2A (0.59) | KMT2ACYP2C9WDR5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111714639-A | Composition comprising histamine release-promoting substance and benzimidazole derivative | 黄泳华 | 2020-09-29 | — | — | CN | claimed |
| CN-111084886-A | Composition comprising fatty acid or derivative thereof and benzimidazole derivative | 黄泳华 | 2020-05-01 | — | — | CN | claimed |
| CN-118010878-A | Determination method and application of impurities in sodium rabeprazole enteric-coated preparation | 丽珠集团丽珠制药厂 | 2024-05-10 | — | — | CN | disclosed |
| CN-118010878-A | Determination method and application of impurities in sodium rabeprazole enteric-coated preparation | 丽珠集团丽珠制药厂 | 2024-05-10 | — | — | CN | disclosed |
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| CN-111714639-A | Composition comprising histamine release-promoting substance and benzimidazole derivative | 黄泳华 | 2020-09-29 | — | — | CN | disclosed |
| CN-111084886-A | Composition comprising fatty acid or derivative thereof and benzimidazole derivative | 黄泳华 | 2020-05-01 | — | — | CN | disclosed |
| CN-103483320-B | Synthetic method of Rabeprazole Sulfone (2-[[[4-(3-methoxy propoxy)-3-methyl-2-pyridyl] methyl] sulfonyl]-1H-benzimidazole) | JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEV CO LTD | 2014-12-03 | — | — | CN | disclosed |
| CN-103483320-B | Synthetic method of Rabeprazole Sulfone (2-[[[4-(3-methoxy propoxy)-3-methyl-2-pyridyl] methyl] sulfonyl]-1H-benzimidazole) | JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEV CO LTD | 2014-12-03 | — | — | CN | disclosed |
| CN-103483320-A | Synthetic method of Rabeprazole Sulfone (2-[[[4-(3-methoxy propoxy)-3-methyl-2-pyridyl] methyl] sulfonyl]-1H-benzimidazole) | JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEV CO LTD | 2014-01-01 | — | — | CN | disclosed |
| EP-1775292-A1 | SALTS OF BENZIMIDAZOLE DERIVATIVE WITH AMINES AND PROCESS FOR PRODUCTION THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007023393-A2 | NOVEL PROCESSES FOR THE PRODUCTION OF AMORPHOUS RABEPRAZOLE SODIUM | MEDICHEM, S.A. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023393-A2 | NOVEL PROCESSES FOR THE PRODUCTION OF AMORPHOUS RABEPRAZOLE SODIUM | MEDICHEM, S.A. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023393-A2 | NOVEL PROCESSES FOR THE PRODUCTION OF AMORPHOUS RABEPRAZOLE SODIUM | MEDICHEM, S.A. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1409478-B1 | IMPROVED PROCESS FOR PREPARING BENZIMIDAZOLE-TYPE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-29 | — | — | EP | disclosed |
| US-6919459-B2 | Process for preparing benzimidazole-type compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-19 | — | — | US | disclosed |
| US-20040209918-A1 | Process for preparing benzimidazole-type compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-21 | — | — | US | disclosed |
| EP-1409478-A1 | IMPROVED PROCESS FOR PREPARING BENZIMIDAZOLE-TYPE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003008406-A1 | IMPROVED PROCESS FOR PREPARING BENZIMIDAZOLE-TYPE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209918-A1 | Process for preparing benzimidazole-type compounds | SQOR, CYP2B6, CYP3A5 | KMT2A 3547/4885CYP2C9 27/4885WDR5 4069/4885 |
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | KMT2A 3380/4885CYP2C9 4152/4885WDR5 3395/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | KMT2A 3380/4885CYP2C9 4152/4885WDR5 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.